|
|
Vaccine Detail
|
Pfs25-EPA / AS01 |
| Vaccine Information |
- Vaccine Name: Pfs25-EPA / AS01
- Target Pathogen: Plasmodium spp.
- Target Disease: Malaria
- Type: Protein-nanoparticle vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- Antigen: Pfs25, a post-fertilization antigen that is involved in ookinete formation and survives in the mosquito midgut (Mulamba et al., 2022)
- Pfs25 from P. falciparum 3D7
gene engineering:
- Type: Recombinant protein preparation
- Description: Pfs25 (or P25) from P. falciparum was used as the vaccine antigen
- Detailed Gene Information: Click Here.
- Preparation: Pfs25 is a leading TBV candidate, and previous studies conducted in animals demonstrated an improvement of its functional immunogenicity after conjugation to EPA, a recombinant, detoxified ExoProtein A from Pseudomonas aeruginosa (Talaat et al., 2016). In addition, AS01 is used as the vaccine adjuvant.
- Immunization Route: Intramuscular injection (i.m.)
- Description: Pfs25-EPA/ AS01 vaccine is made by using the Pfs25 as the vaccine antigen, which is conjugated to EPA nanoparticles, and the GSK platform AS01 serves as the vaccine adjuvant (Talaat et al., 2016).
|
| Host Response |
|
Mouse Response
- Host Strain: CD-1 Mice
- Efficacy: Pfs25-EPA formulated in AS01 induced significantly higher antibody levels than unconjugated Pfs25 formulated in AS01 (Rausch et al., 2023) Pfs25-EPA/AS01 showed significant oocyst reduction compared to Pfs25-EPA/Alhydrogel, but the difference between these groups was not statistically significant at end of study (Rausch et al., 2023)
|
| References |
Mulamba et al., 2022: Mulamba C, Williams C, Kreppel K, Ouedraogo JB, Olotu AI. Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings. Malaria journal. 2022; 21(1); 159. [PubMed: 35655174].
Rausch et al., 2023: Rausch KM, Barnafo EK, Lambert LE, Muratova O, Gorres JP, Anderson C, Narum DL, Wu Y, Morrison RD, Zaidi I, Duffy PE. Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission. iScience. 2023; 26(7); 107192. [PubMed: 37485364].
Talaat et al., 2016: Talaat KR, Ellis RD, Hurd J, Hentrich A, Gabriel E, Hynes NA, Rausch KM, Zhu D, Muratova O, Herrera R, Anderson C, Jones D, Aebig J, Brockley S, MacDonald NJ, Wang X, Fay MP, Healy SA, Durbin AP, Narum DL, Wu Y, Duffy PE. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. PloS one. 2016; 11(10); e0163144. [PubMed: 27749907].
|
|
